Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
CytoDyn, Inc. has selected the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture the Company’s DNA-based pre-flu vaccine. CytoDyn’s pre-flu vaccine provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective. It uses DNA technology to implant a false memory …
Protox Therapeutics Incorporated ("Protox") today announced that it has entered into a manufacturing agreement with the Waisman Clinical BioManufacturing Facility (WCBF) at the University of Wisconsin-Madison to manufacture clinical batches of PSA-PA1, its lead product in development for the treatment of localized prostate cancer.
The University of Wisconsin-Madison's Waisman Center will celebrate the completion of a $25 million expansion project with dedication ceremonies scheduled for Tuesday, September 4. The new facilities will support the center's pioneering research, services, and education in human development, developmental disabilities, and neurodegenerative diseases.
